New research supports role for crenolanib

/New research supports role for crenolanib

New research supports role for crenolanib

By |2013-01-08T13:41:40-04:00August 1st, 2012|D842V, News|

A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent of GISTS.

Crenolanib is an investigational new drug being developed by AROG Pharmaceuticals. Crenolanib is a tyrosine kinase inhibitor that acts by inhibiting PDGFRA and PDGFRB.

The study was done by Michael C. Heinrich and colleagues and was titled “Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors.”

Based in part on these results, a phase II clinical study has been initiated.

Recent Posts

Upcoming Events

  1. GDOL Vancouver logo

    GIST Day of Learning – Vancouver

    April 27 @ 9:00 AM - 4:00 PM
  2. GIST DO IT NJ

    May 4 @ 8:00 AM - 11:00 AM